Literature DB >> 21878884

Transplantation: mTOR inhibition in kidney transplant recipients.

Sarah E Yost, Rochelle Byrne, Bruce Kaplan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21878884     DOI： 10.1038/nrneph.2011.125

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  8 in total

1.  Reduced exposure to calcineurin inhibitors in renal transplantation.

Authors:  Henrik Ekberg; Helio Tedesco-Silva; Alper Demirbas; Stefan Vítko; Björn Nashan; Alp Gürkan; Raimund Margreiter; Christian Hugo; Josep M Grinyó; Ulrich Frei; Yves Vanrenterghem; Pierre Daloze; Philip F Halloran
Journal:  N Engl J Med       Date:  2007-12-20       Impact factor: 91.245

2.  The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients.

Authors:  S M Flechner; M Glyda; S Cockfield; J Grinyó; Ch Legendre; G Russ; S Steinberg; K M Wissing; S S Tai
Journal:  Am J Transplant       Date:  2011-06-10       Impact factor: 8.086

3.  Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine.

Authors:  Stuart M Flechner; David Goldfarb; Charles Modlin; Jingyuan Feng; Venkatesh Krishnamurthi; Barbara Mastroianni; Kathy Savas; Daniel J Cook; Andrew C Novick
Journal:  Transplantation       Date:  2002-10-27       Impact factor: 4.939

4.  Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.

Authors:  Josefina Alberú; Michael D Pascoe; Josep M Campistol; Francesco P Schena; Maria Del Carmen Rial; Martin Polinsky; John F Neylan; Joan Korth-Bradley; Robert Goldberg-Alberts; Eric S Maller
Journal:  Transplantation       Date:  2011-08-15       Impact factor: 4.939

5.  Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.

Authors:  Hallvard Holdaas; Lionel Rostaing; Daniel Serón; Edward Cole; Jeremy Chapman; Bengt Fellstrøm; Erik H Strom; Alan Jardine; Karsten Midtvedt; Uwe Machein; Bettina Ulbricht; Alexander Karpov; Philip J O'Connell
Journal:  Transplantation       Date:  2011-08-27       Impact factor: 4.939

6.  Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.

Authors:  Y Lebranchu; A Thierry; O Toupance; P F Westeel; I Etienne; E Thervet; B Moulin; T Frouget; Y Le Meur; D Glotz; A-E Heng; C Onno; M Buchler; S Girardot-Seguin; B Hurault de Ligny
Journal:  Am J Transplant       Date:  2009-05       Impact factor: 8.086

7.  Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.

Authors:  Francesco P Schena; Michael D Pascoe; Josefina Alberu; Maria del Carmen Rial; Rainer Oberbauer; Daniel C Brennan; Josep M Campistol; Lorraine Racusen; Martin S Polinsky; Robert Goldberg-Alberts; Huihua Li; Joseph Scarola; John F Neylan
Journal:  Transplantation       Date:  2009-01-27       Impact factor: 4.939

8.  Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids.

Authors:  M Büchler; S Caillard; S Barbier; E Thervet; O Toupance; H Mazouz; B Hurault de Ligny; Y Le Meur; A Thierry; F Villemain; A-E Heng; B Moulin; M P Morin; C Noël; Y Lebranchu
Journal:  Am J Transplant       Date:  2007-09-14       Impact factor: 8.086
  8 in total
  6 in total

Review 1.  Everolimus and sirolimus in transplantation-related but different.

Authors:  Jost Klawitter; Björn Nashan; Uwe Christians
Journal:  Expert Opin Drug Saf       Date:  2015-04-26       Impact factor: 4.250

2.  The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model.

Authors:  Chie Emoto; Tsuyoshi Fukuda; Raja Venkatasubramanian; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2015-10-28       Impact factor: 4.335

3.  Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling.

Authors:  Stefanie Jeruschke; Anja Katrin Büscher; Jun Oh; Moin Ahson Saleem; Peter Friedrich Hoyer; Stefanie Weber; Perihan Nalbant
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

4.  Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content.

Authors:  C Emoto; T Fukuda; S Cox; U Christians; A A Vinks
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-07-24

5.  Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren's syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?

Authors:  Jasper C A Broen; Joel A G van Roon; Sofie L M Blokland; Maarten R Hillen; Catharina G K Wichers; Maili Zimmermann; Aike A Kruize; Timothy R D J Radstake
Journal:  RMD Open       Date:  2019-01-11

6.  Long-term mTOR inhibitors administration evokes altered calcium homeostasis and platelet dysfunction in kidney transplant patients.

Authors:  Esther López; Alejandro Berna-Erro; Nuria Bermejo; José María Brull; Rocío Martinez; Guadalupe Garcia Pino; Raul Alvarado; Ginés María Salido; Juan Antonio Rosado; Juan José Cubero; Pedro Cosme Redondo
Journal:  J Cell Mol Med       Date:  2013-04-12       Impact factor: 5.310
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.